Abstract
Background: Selenium Nanoparticles (Se-NPs) are known for their antioxidant and anti-inflammatory activities, which are effective in preventing oxidative damage and improving physiological processes.
Objectives: This study aimed at investigating the effects of biosynthesized Se-NPs on bone marrow-derived Endothelial Progenitor Cells (bone marrow-derived EPCs) and blood-derived endothelial progenitor cells (blood-derived EPCs) isolated from rabbits in vitro.
Methods: The cultured EPCs incubated with biosynthesized Se-NPs at the concentrations of 0.19, 0.38, 0.76, 1.71, 3.42, 7.03, 14.25, 28.50, 57, 114, and 228μg/ml for 48h. After screening the proliferative potential of the Se-NPs by the MTT assay, the best concentrations were selected for Real-Time quantitative Polymerase Chain Reaction (RT-qPCR). Real-time quantification of Vascular Cell Adhesion Molecule 1 (VCAM-1), lectin-like oxidized Low-Density Lipoprotein (LDL) receptor-1 (LOX-1), endothelial Nitric Oxide Synthase (eNOS), and Monocyte Chemoattractant Protein-1 (MCP-1) gene expressions were analyzed by normalizing with Glyceraldehyde- 3-Phosphate Dehydrogenase (GAPDH) as an endogenous reference gene.
Results: Blood-derived EPCs and bone marrow-derived EPCs showed morphological differences before treatment in vitro. Se-NPs treated EPCs indicated a significant dose-dependent proliferative activity (p<0.01). In general, the expression levels of VCAM-1, LOX-1, and MCP-1 mRNA were significantly decreased (p<0.01), whereas that of the eNOS expression was significantly increased at the concentrations of 7.3 and 14.25μg/ml (p<0.01). Although the expressions of MCP-1, LOX-1, and eNOS mRNA were decreased at certain concentrations of Se-NPs (p<0.01 and p<0.05, respectively) in the treated bone marrow-derived EPCs, no significant differences were observed in the VCAM-1 mRNA expression levels in bone marrow-derived EPCs compared with the control group (p>0.05).
Conclusion: This was the first report to demonstrate the effects of Se-NPs on proliferative, anti-oxidative, and anti-inflammatory activities for bone marrow-derived EPCs and blood-derived EPCs. Our findings suggested that Se-NPs could be considered as an effective agent that may ameliorate vascular problems.
Keywords: Se-NPs, EPCs, proliferation, inflammation, anti-oxidative, eNOS.
Graphical Abstract
[http://dx.doi.org/10.1002/etc.1995] [PMID: 22927138]
[PMID: 26464812]
[http://dx.doi.org/10.1038/srep31427] [PMID: 27514819]
[http://dx.doi.org/10.1007/s12011-015-0387-3] [PMID: 26051789]
[http://dx.doi.org/10.2147/IJN.S162355] [PMID: 29662312]
[http://dx.doi.org/10.1071/AN17057]
[http://dx.doi.org/10.1016/j.addr.2009.11.007] [PMID: 19914317]
[http://dx.doi.org/10.5772/8508]
[http://dx.doi.org/10.1002/cbf.3249] [PMID: 28150318]
[http://dx.doi.org/10.1016/j.jtemb.2016.09.003] [PMID: 27908405]
[http://dx.doi.org/10.1007/s10616-010-9329-2] [PMID: 21331655]
[http://dx.doi.org/10.1242/dev.02315] [PMID: 16524930]
[http://dx.doi.org/10.3892/mmr.2013.1718] [PMID: 24126824]
[http://dx.doi.org/10.1182/blood-2004-04-1396] [PMID: 15226175]
[http://dx.doi.org/10.1007/s10456-012-9257-1] [PMID: 22382584]
[PMID: 10667463]
[http://dx.doi.org/10.1016/S0304-3835(97)00497-7] [PMID: 9566703]
[http://dx.doi.org/10.1002/adfm.201401263]
[http://dx.doi.org/10.1016/j.critrevonc.2012.09.014] [PMID: 23098684]
[http://dx.doi.org/10.1016/j.freeradbiomed.2014.04.003] [PMID: 24727439]
[http://dx.doi.org/10.1620/tjem.221.19] [PMID: 20448437]
[http://dx.doi.org/10.3109/10520295.2015.1042050] [PMID: 25978137]
[http://dx.doi.org/10.1159/000443041] [PMID: 26909517]
[http://dx.doi.org/10.1155/2013/152786] [PMID: 23935243]
[PMID: 12061080]
[http://dx.doi.org/10.1016/S0021-9150(01)00672-4] [PMID: 11888521]
[http://dx.doi.org/10.1186/s13054-015-0774-3] [PMID: 25886988]